To explore the clinical effect mechanism of acupoint therapy in patients with asthma at remission stage. Methods:A total of 90 patients with asthma at remission stage who were admitted and treated in Wuhan First Hospital from January 2015 to June 2016 were selected and divided into group A (acupoint therapy), group B (acupoint injection) and group C (seretide) according to the random number table with 30 cases in each group. The treatment last 8 weeks. The asthma control situation (full control, portion control, no control) after two months' treatment (short-term) and 3 months after stopping treatment (long-term), and cortisol (COR), Interleukin-5 (IL-5), Interleukin-10 (IL-10), T lymphocytes (CD4+, CD8+, CD4+/CD8+) before treatment, after two months' treatment (short-term) and 3 months after stopping treatment (long-term) of patients in three groups were observed, and clinical efficacy in short-term and long-term, as well as the levels of COR, CD4+, CD8+, CD4+/CD8+, IL-5 and IL-10 in the three groups were statistically analyzed. Results:In short-term efficacy, the total effective rate of group A (96.67%) was significantly better than group B (80.00%) and group C (66.67%) with statistical significance (P<0.05); In long-term efficacy, the total effective rate of group A (93.33%) was significantly better than group B (76.67%) and group C (63.33 %) with statistical significance (P<0.05); Compared with group B and group C, the levels of COR, CD4+, CD8+, CD4+/CD8+, IL-5 and IL-10 in group A were significantly improved with statistical significance (P<0.05). Conclusion:Acupoint therapy may improve the changes of COR, CD4+, CD8+, CD4+/CD8+, IL-5, IL-10 in patients with asthma by supplementing the kidney, strengthening the spleen and smoothing the lungs, so as to improve the clinical curative effect.